Vitamin D supplementation can reduce the incidence of advanced cancer among older adults, in particular those with a normal BMI but not those who are overweight or obese, suggests the large VITAL* randomized study presented during the ASCO 2020 Meeting.
Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.
Three years of adjuvant imatinib treatment is superior in efficacy vs 1-year use in patients with gastrointestinal stromal tumours (GIST) at high risk of recurrence post-surgery, according to the secondary analysis of the SSGXVIII/AIO* trial.
The combination therapy of pembrolizumab + axitinib continued to demonstrate significant improvements in overall survival (OS) and progression-free survival (PFS) among patients with advanced renal cell carcinoma (RCC) over an extended 24-month follow-up, according to the KEYNOTE-426* study presented at ASCO20 Virtual Scientific Program.
Adjuvant treatment with dabrafenib plus trametinib prolongs relapse-free survival (RFS) in patients with resected stage III BRAF V600-mutant melanoma, according to a 5-year analysis of the COMBI-AD* study presented at the ASCO20 Virtual Scientific Program.
The investigational, highly selective MET inhibitor savolitinib demonstrated encouraging efficacy and safety vs standard-of-care sunitinib in patients with MET-driven*, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC), according to the phase III SAVOIR trial results presented at ASCO 2020.
Pembrolizumab as first-line therapy significantly improves progression-free survival (PFS) vs chemotherapy in patients with microsatellite instability-high (MSI-H)/mismatch-repair deficient (dMMR) metastatic colorectal cancer (mCRC), according to results of the KEYNOTE-177 study reported at the American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Programme.
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.